The company's paediatric phase 3 PARADIGMS study met its primary endpoint, showing a significant reduction in relapses in patients treated with Gilenya (fingolimod) versus Biogen’s Avonex ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback